On Thursday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Cellectis S.A. (NASDAQ:CLLS), Neuralstem, Inc. (NYSEMKT:CUR), Cloud Peak Energy Inc. (NYSE:CLD), XOMA Corporation (NASDAQ:XOMA)
Cellectis S.A. (NASDAQ:CLLS), with shares declined -4.96%, closed at $37.35, hitting new 52-week low of $34.86.
Neuralstem, Inc. (NYSEMKT:CUR), with shares dropped -4.72%, settled at $2.02, hitting new 52-week low of $1.78.
Cloud Peak Energy Inc. (NYSE:CLD), with shares dipped -4.61%, and closed at $6.21.
XOMA Corporation (NASDAQ:XOMA), plummeted -2.97%, and closed at $3.59.
Latest NEWS regarding these Stocks are depicted underneath:
Cellectis S.A. (NASDAQ:CLLS)
NASDAQ (NDAQ) declared that trading of Cellectis S.A. (CLLS), commenced on The NASDAQ Stock Market on March 25, 2015.
Cellectis is a pioneering gene-editing corporation focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). Cellectis is dedicated to developing new types of cancer therapies based on these cells. The Corporation’s gene-editing technologies give the ability to create allogeneic CAR T-cells, meaning they are derived from healthy donors rather than the patients themselves.
Neuralstem, Inc. (NYSEMKT:CUR)
Formerly on March 16, Neuralstem, Inc. (CUR), stated its financial results for the fourth quarter and year ended December 31, 2014.
2014 Clinical Program and Business Highlights:
- NSI-189 Phase II clinical trial for the treatment of MDD is predictable to commence in the second quarter of 2015. Maurizio Fava, M.D., Slater Family Professor of Psychiatry at Harvard Medical School, Massachusetts General Hospital is the principal investigator for the 150-patient, multi-site clinical trial.
- Top-line data for the NSI-189 Phase Ib MDD trial. The data was presented at the American Society of Clinical Psychopharmacology (ASCP) and the International College of Neuropyschopharmacology (CiNP) annual meetings. The randomized, placebo-controlled, dose-escalation study showed clinically meaningful and statistically noteworthy results in depressive and cognitive measurements at the end of the 28-day dosing period. Moreover, therapeutic benefits were sustained over the 8-week follow-up period signaling possible hippocampal neurogenesis.
- NSI-189 MDD biomarker data. In November 2014, researchers presented Phase Ib blood-based biomarker data and analysis for MDD in a poster at the CNS Summit, which identified a rapid and persistently efficacious response.
- Expansion of NSI-189 development program to a second indication for the treatment of cognitive deficit in schizophrenia. Cognitive deficit in schizophrenia is a prominent characteristic of the disorder that is correlated with the occurrence of hippocampal atrophy in this patient population. Commencement of the Corporation’s NSI-189 cognitive deficit in schizophrenia Phase Ib trial is predictable in 2015.
Neuralstem, Inc., a biopharmaceutical corporation, focuses on the development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and small molecule compounds. The corporation’s stem cell technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of all types.
Cloud Peak Energy Inc. (NYSE:CLD)
Formerly on March 16, Cloud Peak Energy Inc. (CLD), declared that Colin Marshall, Cloud Peak Energy’s President and Chief Executive Officer, spoke at the Scotia Howard Weil 2015 Energy Conference on Wednesday, March 25, 2015 in New Orleans, Louisiana.
Cloud Peak Energy Inc., through its auxiliaries, produces coal in the Powder River Basin (PRB) and the United States. The corporation operates through Owned and Operated Mines, Logistics and Related Activities, and Corporate and Other segments. It produces and sells sub-bituminous thermal coal with low sulfur content primarily to electric utilities operating in the United States and internationally.
XOMA Corporation (NASDAQ:XOMA)
Formerly on March 11, XOMA Corporation (XOMA), stated its operational highlights and financial results for the quarter and year ended December 31, 2014.
“The fourth quarter was focused on driving enrollment in all five of our gevokizumab Phase 3 clinical trials, concluding our first XOMA 358 clinical study, and putting the Corporation on a strong financial footing to allow us to achieve our aim of transforming XOMA into a commercial organization marketing our products to the U.S. specialist prescriber,” stated John Varian, Chief Executive Officer of XOMA. “Our clinical and regulatory teams are compiling the documentation required to submit a Biologics Licensing Application, in anticipation of positive EYEGUARD-B clinical results and FDA interactions. By investing noteworthy time now, we are doing all we can to expedite the process of requesting a pre-BLA meeting with FDA if we obtain positive primary endpoint results.
“With the encouraging proof-of-concept results in Scleritis, we have identified another potential indication for gevokizumab, and with the successful completion of the XOMA 358 Phase 1 study, we have demonstrated our ability to expand our product pipeline with another internally discovered compound that may lead to therapies for people who are living with conditions that are in clear need of new treatment options,” Mr. Varian concluded.
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The corporation’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
